SEARCH

SEARCH BY CITATION

References

  • 1
    Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352: 168595.
  • 2
    Navab M, Ananthramaiah GM, Reddy ST et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45: 9931007.
  • 3
    Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 50816.
  • 4
    Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006; 98: 9P17P.
  • 5
    Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 43744.
  • 6
    Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 87991.
  • 7
    Baldus S, Heeschen C, Meinertz T et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 14405.
  • 8
    Brennan ML, Penn MS, Van Lente F et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595604.
  • 9
    Rana JS, Arsenault BJ, Despres JP et al. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur Heart J 2011; 32: 33644.
  • 10
    Meuwese MJ, Stroes ESG, Hazen SL et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. J Am Coll Cardiol 2007; 50: 15965.
  • 11
    Hense HW, Filipiak B, Döring A, Stieber J, Liese A, Keil U. Ten-year trends of cardiovascular risk factors in the MONICA Augsburg Region in Southern Germany. Results from the 1984/85, 1989/90 and 1994/1995 surveys. CVD Prev 1998; 1: 31827.
  • 12
    Koenig W, Khuseyinova N, Baumert J et al. Increased concentrations of C-reactive protein and Il-6 but not Il-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006; 26: 274551.
  • 13
    Meisinger C, Thorand B, Schneider A, Stieber J, Döring A, Löwel H. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med 2001; 162: 829.
  • 14
    Holvoet P, Macy E, Landeloos M et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006; 52: 7604.
  • 15
    Müller S, Martin S, Koenig W et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 80512.
  • 16
    Thorand B, Baumert J, Chambless L et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006; 26: 398405.
  • 17
    Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000; 46: 9348.
  • 18
    Thorand B, Baumert J, Kolb H et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007; 30: 85460.
  • 19
    Herder C, Baumert J, Thorand B et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006; 29: 214752.
  • 20
    Chambless LE, Diao G. Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 2006; 25: 347486.
  • 21
    Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 15772; discussion 207-12.
  • 22
    Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011; 30: 2238.
  • 23
    Andelid K, Bake B, Rak S, Linden A, Rosengren A, Ekberg-Jansson A. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir Med 2007; 01: 88895.
  • 24
    Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 92835.
  • 25
    Ferrante G, Nakano M, Prati F et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes. Circulation 2010; 122: 250513.
  • 26
    Sugiyama S, Kugiyama K, Aikawa M, Makamura S, Ogawa H, Libby P. Hypochlorus acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 130914.
  • 27
    Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005; 112: 6517.
  • 28
    Heilman K, Zilmer M, Zilmer K et al. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Diabetes Res Clin Pract 2009; 84: 16873.
  • 29
    Ali C, Sarcia P, Mosley Jr TH, Kondragunta V, Kullo IJ. Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease. Vasc Med 2009; 14: 21520.
  • 30
    Tang WH, Katz R, Brennan ML et al. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol 2009; 103: 126974.
  • 31
    Reynolds WF, Rhees J, Maciejewski D et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer′s disease. Exp Neurol 1999; 155: 3141.
  • 32
    Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF. Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. J Lipid Res 2006; 47: 136677.
  • 33
    Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the 2463GA promoter polymorphism. J Biol Chem 2004; 279: 830015.